Most recently, Hung and colleagues identified hRNase5/ANG as an EGFR ligand to induce its binding to EGFR and activate EGFR signaling in an RNase catalytic-independent manner, which highlights an oncogenic role of the hRNase5/ANG-EGFR axis in pancreatic cancer [46]. This evidence concerns the gene EGFR and familial pancreatic carcinoma.